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SYSTEMIC VITAMIN D AND FISH OIL IN  
THE MANAGEMENT OF PSORIASIS 
KERRI LISKA 
ABSTRACT 
Data from studies looking at the use of systemic vitamin D and omega-3 fatty acids 
independently in the treatment of psoriasis has shown that both these supplements have at 
least a modest effect when taken in above average doses. Recent advances in the 
understanding of the pathophysiology of psoriasis as well as the immunomodulatory and 
anti-inflammatory properties of these supplements suggest that they could have an 
additive effect in treating this life-long disease. The proposed study is a randomized 
placebo-controlled trial that aims to explore this supposition by supplying 
demographically diverse subjects, who have varying levels of psoriasis severity, with 4g 
of Omacor® fish oil (1.8g EPA + 1.5g DHA) and 4000IU of vitamin D3 (cholecalciferol) 
or placebo pills on top of their existing treatment regimen. The subjects will have a 
baseline evaluation and the trial will run for 1 year with 12 week follow up intervals. 
Every 12 weeks the subjects will have a clinician calculate their current PASI score and 
have blood drawn to measure vitamin D levels. Investigators will analyze the overall 
percent reduction of an individual’s PASI score as well as the mean final PASI scores of 
the intervention and control groups. The data from this study will provide information 
that could add another safe, inexpensive, and effective treatment modality to the 
dermatologist’s arsenal. 
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INTRODUCTION 
Background 
Psoriasis is a chronic cutaneous T-cell mediated inflammatory disease that affects about 
up to 3% of the population in the countries of the Western world.1 Difference in 
prevalence and severity depends on a host of environmental and genetic factors. The 
majority of patients diagnosed with psoriasis have mild-moderate disease.2 The definition 
of mild, moderate, and severe disease is largely subjective based on clinician’s 
assessment and the patient’s perception of quality of life.  
 There are several presentations of psoriasis ranging from scattered papules that 
are a few millimeters to large plaques that encompass almost the entire body. Psoriatic 
plaques are a result of hyperproliferation and early maturation of keratinocytes3 as well as 
infiltration of inflammatory and immune cells. This thickened epidermis along with 
inflammatory cells creates the well-demarcated, raised, erythematous lesions with a 
silver-white scale seen in classic plaque psoriasis.  
 There is no cure for psoriasis therefore the treatments available are for symptom 
management and are chosen based on the severity of the disease, aiming to balance risk 
with benefit. Topical medications such as retinoids, vitamin D derivatives and 
corticosteroids are indicated as monotherapy for mild disease and as adjuvant therapy in 
moderate to severe cases. Phototherapy with narrow band ultraviolet B (UVB) is used as 
second line treatment for psoriasis not adequately controlled with topical medications. 
Systemic oral medications such as chemotherapeutics and phosphodiesterase 4 (PDE4) 
inhibitors as well as injectable biologic agents are reserved for moderate and severe 
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disease given a host of possible adverse events. Despite a great deal of efficacy with these 
medications, patients with psoriasis often have some level of recalcitrant disease that 
requires combination therapy.  
Statement of the Problem 
Adherence to treatment regimens utilizing the currently available medications is a 
significant problem in this life-long disease. Topical medications are often messy, time 
consuming and many find them ineffective. Systemic medications are easier to take, but 
have significant possible side effects or adverse events and are often prohibitively 
expensive. These are often not covered by insurance until patients have failed several 
other less expensive medications, which can lead to weeks to months of living with a 
psychosocially debilitating level of disease. These obstacles to treatment adherence beg 
the question: Is there an effective treatment for this disease that is easy to administer, cost 
effective, and has minimal possible side effects/adverse events? 
Hypothesis 
Combination treatment with cholecalciferol and omega-3 fish oil will significantly 
decrease the Psoriasis Area and Severity Index (PASI) score in patients with chronic 
plaque psoriasis 
Objectives and specific aims 
Psoriasis is an autoimmune disorder that involves dysregulated cell proliferation and 
turnover as well as inflammation. There is significant data on the use of each vitamin D 
and fish oil in the treatment of other hyperproliferative and inflammatory conditions. 
Several studies show the use of topical vitamin D, oral vitamin D and oral fish oil 
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supplementation can be efficacious in psoriasis. There is also data suggesting a 
cumulative or synergistic relationship between these two supplements in the treatment of 
other conditions. There is biological rationale that could explain the mechanism by which 
these supplements could affect the underlying pathogenesis of this disease. This study 
aims to explore whether the natural supplements of vitamin D and fish oil, in 
combination, can provide a safe, efficacious, simply administered, cost effective 
treatment for patients with psoriasis.  
• To show a statistically significant decrease in percent PASI score reduction in 
patients treated with cholecalciferol and omega-3 fish oil in a clinical trial 
• To determine the magnitude of effect of the proposed treatment 
• To determine if severity of disease has an impact on magnitude of effect 
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REVIEW OF THE LITERATURE 
Overview 
 Psoriasis is an autoimmune, T cell mediated disease of systemic inflammation 
with skin, nail, joint and soft tissue manifestations that affects up to 11% of the 
population depending on regional variations.4 Incidence of the disease is not well studied, 
but  a review of 3 studies by Parisi et al estimated the incidence to range from 73-
230/100,000 person years. There is a bimodal distribution of the age of onset, peaking 
from 30-39 and again between 50 and 70. 1 It is a heterogenous disease with many 
different manifestations and varying degrees of severity. Chronic plaque psoriasis is well-
demarcated erythematous, raised plaques with silver grey scale that can range from a few 
millimeters to entire scalps, limbs or trunks. Lesions may also present as small diffusely 
distributed papules (guttate psoriasis), pustules on the hands and feet (palmoplantar 
pustulosis), generalized erythema that is not in well defined plaques (erythrodermic 
psoriasis), plaques clustered in the folds of the skin, particularly inframmamary, perineal 
and axillary, without scale (inverse psoriasis), or rarely generalized inflamed skin studded 
with pustules (pustular psoriasis). These different forms of psoriasis may be symptomatic 
with a burning or itching sensation and may arise acutely or exist for years as chronic 
lesions.5 Environmental triggers can cause the acute lesions seen in guttate psoriasis, 
which is often precipitated by a streptococcal infection. Trauma to the skin of a psoriatic 
patient can also result in new lesions, a process known as Koebnerization. Many patients 
also experience seasonal variation in the severity of their disease, with more severe 
symptoms commonly occurring during cooler, less sunny months.  
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 These above mentioned differences in incidence and prevalence are thought to be 
a combination of environmental as well as genetic factors. Several twin studies show 
significant concordance between siblings.4 The search for certain susceptibility genes is 
an ongoing process. Many different human leukocyte antigen (HLA) genes6, segments of 
several “gene dense” chromosomes named PSORS1-PSORS134,5,7 and many other genes 
are implicated in the disease (see table 1). PSOR1, in particular the major histone 
complex I (MHCI) genes in this chromosome segment have the strongest association with 
psoriasis.4,7  
 The fact that in many patients there is a correlation between severity of disease 
and the season, with being more severe psoriasis occuring in the winter months when 
there is less sunit is cool and dry, is good evidence that there is also an environmental 
factor at play. The Koebner phenomenon, in which trauma triggers an eruption of 
psoriasis, is another indicator that the physical environment plays a role. Guttate 
psoriasis, which can beis usually correlated with a streptococcal infection, is yet another 
clue to the role of exogenous factors in the pathogenesis of this disease.8  
 The difference in prevalence of psoriasis in sub-Saharan Africa represents another 
prime example. The tropical climate of Western Africa shows the lowest prevalence at 
0.05-0.4% whereas the dry area of Eastern Africa has an almost 10x increase in 
prevalence (2.8-3.5%) and yet these populations do not appear to have a difference in the 
frequency of HLA-Cw6. 4,6  The highest rates of psoriasis in the aforementioned review 
by Raychaudhuri et al. occurred in a population that resides in the Artic Circle.6.  
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Table 1. List of Reported Genetic Associations  
(adapted from table 1. in Genetic and epigenetic basis of psoriasis pathogenesis by 
Chandra et al)7 
        A summarized list of genetic associations reported in psoriasis. 
Genetic locus identified Predicted candidate Genes associated 
6p21.33 (PSORS1) 
HLA-Bw7, DR4, DR7, HLA-A1, HLA-B13, 
B17, B27, B39, B57, HLA-Cw6, Cw7, 
PSORS1C3, CCHCR1, CDSN, POU5F1, 
CDKAL1, IRF4 
17q25.3 (PSORS2) 
NAT9, SLC9A3R1, RAPTOR, CMRF35A1, 
CMRF35A2-6, CMRF35H, CARD14, 
STAT3 
4q (PSORS3) IL2, IL21 
1q21 (PSORS4) 
LOR, S100A8, S100A9, PGLYRP3, 
PGLYRP4, LCE3A, LCE3B/3C deletion, 
LCE3D, LCE3E, IVL, FLG 
3q21 (PSORS5) CSTA, SLC12A8 
19p13 (PSORS6) Jun-B, ILF3, BSG 
1p (PSORS7) EPS15, IL23R, PTPN22, RUNX3, TNFRSF9 
16q (PSORS8) NOD2, CARD15, CYLD 
4q31-34 (PSORS9) IL15 
18p11.23 (PSORS10)  
5q31.1-q33.1 (PSORS11) IL12B, IL13, TNIP1 
20q13 (PSORS12) RNF114, SPATA2, ZNF313 
6q21 (PSORS13) TRAF3IP2, TAGAP 
14q12 TGM1 
3p24 IL17RD 
5q15 ERAP1 
11q24.3 ETS1, ZC3H12C 
13q21-32  
13q11-12 GJB2 
19q13 ZNF816A, FUT2 
20p13 TGM3, ADAM33 
15q15.2 TGM5 
16p13.13 SOCS1 
9q33-34 KLF4 
2p22.3 IL1RN 
18q21.2 MBD2 
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 Older epidemiologic studies show an absence of psoriasis in Aborigines, Andean 
Indians, Amerindians, and Native Americans and more recent genetic assessments have 
shown a lack of several of the HLA loci associated with psoriasis.4,6 These races live in a 
variety of environments that would contribute differently to the prevalence of disease, but 
consistently lack known susceptibility genes. Chandra et al. reviewed several family 
based studies and came to the conclusion that though there are many genes associated 
with psoriasis, it is a heterogenic disease..7 Clearly disease incidence and severity 
represent an interplay between genetics and environment 
 A German study published in 1970 discovered the possible immunologic basis of 
psoriasis and, since that time, there have been several other studies substantiating that 
claim that dysregulation of the immune system could be to blame for the overactive 
turnover of keratinocytes found in psoriasis.3 An article in the New England Journal of 
Medicine by Nestle et al. summarized several studies which found increased numbers of 
dendritic cells, T cells and cytokines in psoriatic skin.3  
This review will explore both the innate and adaptive immune response and the 
cytokine mediators that play a key role in the proposed intervention. Keratinocytes play a 
large role in the activation of the innate immune system, sending out cytokines to attract 
T cells and dendritic cells to the areas of skin. Trauma or infection can also stimulate the 
activity of dendritic cells, which further activates T cells. The main pathway for immune 
activation in psoriasis is mediated by interleukin-23 (IL-23) release from activated 
dendritic cells as well as keratinocytes (see figure 1). IL-23 stimulates survival and 
proliferation of T helper 17(Th17) cells.9,10 Th17 cells (CD4+) releases IL-17 and IL-22 
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Figure 1. “Immunogenic pathway model in psoriasis” (IL-23/T17 axis (red) is 
dominant pathway). Taken from “The Immunopathogenesis of Psoriasis” by Kim et 
al.9 
which in turn act on keratinocytes.10,11 There are several other types of T cells that can 
produce IL-17 (CD8+, αβ T cells, γδ T cells, innate lymphoid cells) and therefore most 
literature refers to them as T17 cells9 as will be done here for simplicity. Lynda Grine et 
al explained in a 2014 paper looking at the role of tumor necrosis factor (TNF), type I 
interferons (IFNs) and IL-17, that when compared with healthy controls, psoriasis 
patients have a higher level of intralesional and circulating IL-17 and that there is a 
correlation between level of IL-17 and disease severity.10 Psoriatic skin has a 30-fold 
increase in BDCA-1- dendritic cells, which are the “inflammatory” dendritic cells, and 
these have been proposed as a driver of T17 cells.9 According to Yiu and Griffiths who 
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reviewed the effect of several IL-17 medications in psoriasis, “Psoriasis is considered a 
prototypical IL-17-mediated disease.”12  
Prior to the discovery of T17 cell involvement, release of interferon-gamma (IFN-
γ) and tumor necrosis factor-alpha (TNF-α) produced by many cell types, especially Th1 
cells, were thought to be the most important mediators of pathogenesis. These cytokines 
certainly do play a role upstream in the activation and proliferation of immune cells and 
cytokine release.9,13 Kim et al. proposed that IL-17 can synergize with TNF-α to induce 
key genes involved in psoriasis.9 TNF-α, which is produced by keratinocytes, dendritic 
cells and T cells in response to a host of inciting factors, can induce the proliferation of 
dendritic cells, T cells and therefore the release of more TNF-α, IFN-γ, and IL-17.9,10 
There are cytokines in psoriasis that come from every T cell line, but more recent 
experiments exploring the effects of T17 induction and inhibition in psoriatic lesions 
have shown this to be the major factor.9 Furthermore Kim et al. stated in their review that 
IL-17 induces several other interleukins, which might lead to keratinocyte proliferation,9 
a hallmark of this disease.  
Psoriasis is most often evaluated based on the clinical characteristics a provider 
sees in the office. There is a significant amount of morbidity associated with the disease 
including psychological effects, medication side effects, and other associated 
inflammatory diseases such as Crohn’s disease, type 2 diabetes, and cardiovascular 
disease (CVD).3,14 Several assessment scales exist to standardize the clinical evaluation 
of plaque psoriasis. There is a debate on the best method given the diverse presentation 
and amount of subjective data required. 	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Management of psoriasis is based on clinical assessment of severity and risk 
versus benefit of certain medications. Knowledge of immune system involvement in the 
pathogenesis of psoriasis has led to the use of immune targeted therapies such as 
methotrexate and cyclosporine as well as less targeted anti-inflammatories such as topical 
steroids and phototherapy.14 Mild psoriasis is treated with topical medications because 
these often have the lowest risk profile and are capable of controlling limited disease. 
Consensus guidelines published in JAMA in 2012 gloss over the treatment of mild 
disease and simply define it as that which can be treated solely by topical treatment.14  
Moderate to severe disease requires treatment with systemic (oral and/or 
phototherapy) and biologic medications. These both have system wide effects, side 
effects, and require more monitoring than topical therapies. The adverse reactions 
possible with these medications make the risk/benefit acceptable for only those with 
moderate-severe and severe disease.15 Oral systemic medications include methotrexate 
(folate biosynthesis inhibitor) and cyclosporine (calcineurin inhibitor), which inhibit cell 
turnover and cell synthesis, acitretin (an oral retinoid), which regulates gene transcription 
for “nuclear differentiation, antiproliferation, anti-inflammation, antikeratinization and 
inhibition of neutrophil chemotaxis”16, and the newly approved Apremilast (PDE4 
inhibitor) which downregulates the inflammatory response mediated by Th1, Th17 and 
type 1 IFN pathways.14,17 These mediations may also require lifestyle changes such as 
avoiding alcohol, pregnancy, and excessive sunlight.18 Several biologic medications 
exist, some of which inhibit cytokines known to be involved in the pathogenesis of 
psoriasis such as TNF (etanercept, infliximab, adalimumab), IL-12/23 (ustekinumab), and 
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IL-17 (secukinumab, ixekizumab, brodalumab).12,14 The most recent of these biologic 
medications are those targeting IL-17 and only one (secukinumab) is currently on the 
market.12 A review of data from several phase II and III trials of IL-17 inhibitors by Yiu 
et al. showed significant superiority over older treatments and even raised the standard of 
care for those with severe psoriasis showing a consistent, high percentage of patients 
reaching a 90% decrease in PASI score.12  
Treatment adherence with medications is a significant issue. There have been 
several studies looking at patient adherence, which are nicely summarized in literature 
reviews performed by Thorneloe et al. and Saeki et al. Both reviews showed that topical 
medication adherence is worse than systemic treatment modalities.2,19 In a review done 
by Deveaux et al. topical medication non-compliance was largely due to four major 
complaints: time needed to apply treatment, poor efficacy, fear of side effects and 
cosmetic effects. Time commitment was the largest contributor.20  
The review by Saeki et al. also found a significant percentage of what they 
defined as medium and low treatment adherence (32.5% and 55.4% respectively) in the 
oral treatment group, but noted that these percentages decreased with higher annual 
income, a correlation that was not seen in the topical medication group.19 Phototherapy, 
oral, and biologic medications are much more expensive than topical treatment. An 
estimation of monthly costs done by D’Souza and Payette showed prices ranging from 
around $800/month for methotrexate to around $15,200 for infliximab.21   
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Table 2 shows several adverse events that are possible with these systemic 
treatments. Armstrong et al. reviewed findings from National Psoriasis Foundation (NPF) 
surveys of treatment type for mild, moderate, and severe disease done from 2003-2011 
Table 2. Possible Safety Concerns of Systemic Psoriasis Treatments 14 
 
 
and found the most common reason for the use of only topical medication was fewer 
adverse effects. It also showed that as of 2008 the main reason (28%) for discontinuing 
biologic treatment was adverse side effects. They also found that patient satisfaction with 
any form of psoriasis treatment was low at only 47.7% as of 2011.22 For reasons not 
explained in the review up to 49.2% of those with mild, up to 35.5% of those with 
moderate, and up to 29.7% of those with severe disease over the time period studied were 
not receiving treatment at all.22 This could be rationalized by any of the aforementioned 
Phototherapy Oral Biologic 
Skin Cancer 
Nausea (with psoralen) 
Skin aging/freckling 
 
Liver toxicity 
Renal toxicity 
Hypertriglyceridemia 
Teratogenicity 
Abortifacient 
Drug interactions 
Skin cancer 
Serious Infection 
Autoimmune conditions 
Lymphoma 
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reasons for discontinuation or non-adherence: time consumption, expense, and/or adverse 
events. 
Existing research 
Fish Oil 
N-3 fatty acids found in fish oil have been explored as an adjunctive treatment in several 
other inflammatory conditions such as Crohn’s disease, rheumatoid arthritis, and CVD.23 
Like these other diseases, psoriasis is a disease of systemic inflammation. It is proposed 
here that since this supplement has proven efficacious in reducing inflammation in CVD, 
it may have a similar effect in psoriasis. 
The association with CVD is well studied for over 35 years beginning with 
investigations into lipid metabolism and ischemic heart disease in Greenland Eskimos by 
Bang and Dyerberg.24 Hundreds of studies have explored the relationship between N-3 
fatty acids and CVD aiming to find biological pathways to explain the observed benefits. 
Though many studies explored the effects of these polyunsaturated fatty acids (PUFAs) 
on the levels of the lipids involved in CVD they also looked at the connection between 
PUFAs and inflammation.25,26 Inflammation is known to play a large role in 
atherosclerosis.27 A review by Fleming et al. exploring α-linolenic acid (ALA) as 
compared with docosahexaenoic acid (DHA) + eicosapentaenoic acid (EPA) in CVD 
reduction cited several studies which showed that the two components of omega-3 
supplementation (DHA and EPA) had an inverse relationship with several markers of 
inflammation. Increased incorporation of n-3 fatty acids into cell membranes provides 
less substrate for inflammatory eicosanoids (metabolites of PUFA, arachidonic acid 
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(AA), EPA, and dihomogamma linolenic acid oxidation).26,28,29 Two separate reviews of 
the literature looking at fish oil and CVD both showed that there was conflicting evidence 
on the efficacy of fish oil and various mortality and cardiovascular endpoints. In both 
reviews they stated this could be due to a lack of control of fish consumption in the 
control study as well as an estimated omega-3 consumption rather than blood 
monitoring.30,31 They came to the conclusion that despite conflicting data there was 
significant data showing a benefit. Therefore there is a place for fish oil supplementation 
in CVD that is due not only to beneficial changes in lipid profiles but also because of 
anti-inflammatory properties.30,31  
For decades an association between psoriasis and CVD has been seen in the 
hospital setting and been studied by many researchers. Charles McDonald MD and Paul 
Calabresi MD noted almost twice the amount of vaso-occlusive events in psoriatic 
patients at Roger Williams Hospital from 1968-1972. They performed a study that was 
published in 1978 examining the records of 323 psoriatic and 325 non-psoriatic patients 
who were admitted to the dermatology service at Roger Williams Medical Center. In this 
larger, more organized study they still found a significant increase in the amount of 
occlusive vascular events in those with psoriasis.32  
Gelfand et al. found that many studies showing a correlation of psoriasis with 
CVD were done on hospitalized patients. Therefore they did a population based 
prospective study looking at the incidence of myocardial infarction in patients with mild 
or severe psoriasis when compared to demographic and risk factor-matched controls. In 
this study they found that both mild and moderate psoriasis conferred a higher relative 
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risk for younger individuals. Their data showed a relative risk of	  “1.29 (95% CI, 1.14-
1.46) and 3.10 (95% CI, 1.98-4.86)” for mild and severe psoriasis respectively for a 30 
year-old patient with relative risk dropping to “1.08 (95% CI, 1.03-1.13) and 1.36 (95% 
CI, 1.13-1.64), respectively” for a 60 year-old patient.33 When they controlled for major 
cardiovascular risk factors they found the attributable and excessive risk of myocardial 
infarction (MI) due to psoriasis increased with both mild and moderate degrees of 
severity.33 
A study done by Neimann et al. sought to answer the question of whether 
psoriasis could in fact be associated with CVD risk factors. Their literature review 
showed a selection bias of patients with significant additional co-morbidities due to the 
fact that most studies were done on hospitalized patients. Neimann et al. carried out  a 
population-based study and control matched each case with 5 non-psoriatic patients with 
similar demographics. Their data suggested that psoriasis is, in fact, associated with 
metabolic syndrome (hypertension, dyslipidemia, obesity, and impaired glucose 
tolerance) and the association increases with increasing severity of psoriasis. Furthermore 
they explained from review of the literature on metabolic syndrome, that like psoriasis, 
metabolic syndrome is a disease of inflammation involving increased T cell and cytokine 
activity.34 Both have a Th1 inflammatory profile35 and psoriasis is sometimes “included 
in the chronic inflammatory spectrum of the metabolic syndrome.”36 This association 
with metabolic syndrome is fast gaining support and being recognized as a key 
intervention target for psoriasis patients with  lifestyle and diet changes.37  
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Cutaneous inflammation is mediated through eicosanoids produced by skin cells 
in response to injury that aids in repair of the skin. Eicosanoids are therefore a central 
part of many dermatoses such as psoriasis.38 Essential fatty acids provided by the diet, 
omega-6 (AA) and omega-3 (DHA + EPA), are converted into eicosanoids, which have 
both pro-inflammatory and anti-inflammatory properties.38,39 Psoriatic skin is found to 
have higher levels of AA which in turn leads to pro-inflammatory cytokines and the 
attraction of immune cells.39–41 As mentioned above EPA can compete with AA when 
levels are high enough and in turn lead to anti-inflammatory cytokines.26,38,42 According 
to McCusker et al. in a paper on the healing fats of the skin, EPA and DHA are often not 
abundant in the epidermis because of a lack of consumption or increased usage. Diets 
supplemented with fish oil have an alteration in this profile.36 Kendall et al. also 
examined the distribution of bioactive lipids in the skin and they showed that the lipid 
profile in the dermis and epidermis changed with the addition of omega-3 PUFAs to 
include more of the “less inflammatory” eicosanoids, endocannabinoids, and anti-
inflammatory lipid resolvins and maresins.28 
PUFAs also have an immunologic effect. Murine studies done by Allen et al. and 
Monk et al. showed omega-3 influence on Th1, Th2 and Th17 activation and signal 
transduction.43,44 These studies cited information regarding fish oil suppression of CD4+ 
transformation to Th1 inflammatory subset and sought to explore the effects on Th17 
transformation. Allen et al. showed that fish oil incorporation into T cell membranes 
interrupted the signal axis involved in Th17 differntiation.44 As mentioned above, the 
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pathogenesis of psoriasis is greatly driven by Th17 cells and therefore fish oil could play 
a role in suppressing this process. 
Several older studies done in the 1980’s and early 1990’s have looked at topical, 
oral, and IV supplementation with fish oil with little or even no success. Grimminger and 
Mayser reviewed several of the past attempts to test oral supplementation with free fatty 
acids. Many of the studies they reviewed showed modest change in the characteristics of 
psoriatic plaques.39,41 According to Grimminger and Mayser the controlled studies seem 
to show more of a benefit than randomized controlled trials.39 A more recent review by 
Millsop et al in 2014 showed more promising outcomes with 12 of 15 studies showing 
significant improvement with an even split of controlled and uncontrolled studies 
showing significant improvement. They found in their review of several nutritional 
supplements that the data for fish oil, as monotherapy or in combination with topicals, 
phototherapy or retinoids, was the most encouraging. Their findings are summarized in 
appendix A.45  
Not only is CVD a common comorbidity with psoriasis, but both are also diseases 
of systemic inflammation.  Therefore it is proposed that a medication that works by 
decreasing the amount of systemic inflammation in CVD may have a similar effect in 
psoriasis. The epidemiologic reviews cited above noted a significant decrease in coronary 
artery disease, diabetes and psoriasis in the people who live in the artic circle. They 
believe this is possibly due to a diet rich in polyunsaturated fats and both suggest that fish 
oil may be an appropriate supplemental therapy for psoriasis.4,6 The anti-inflammatory 
effects of DHA and EPA in the skin and immunomodulation of fish oil further supports 
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the idea that it could be beneficial in psoriasis. The studies reviewed above also show that 
there is in fact a moderate improvement in the disease. The added benefit in aspects of 
metabolic syndrome and CVD makes fish oil a promising supplement in psoriasis.  
There are many OTC fish oil supplements on the market. The VITAL trial 
currently occurring in affiliation with Brigham and Women’s Hospital in Boston is 
exploring a combination of vitamin D and fish oil supplementation in CVD and cancer 
prevention. In this trial they chose Omacor® fish oil as it “has undergone an extensive 
purification process and is free of environmental toxins (e.g., methylmercury, 
polychlorinated biphenyls [PCBs], and dioxins) found in some fish. It has also undergone 
extensive quality control testing for stability of nutrient content and other parameters at a 
range of temperatures and humidity levels.”46 The ratio of EPA to DHA is 1.3:1 in 
Omacor® fish oil with 465mg EPA and 375mg of DHA per 1gm capsule. Through the 
intense purification process these capsules have a very minimal “fishy” smell and taste.47 
The VITAL trial suggested that 1gm of fish oil, or 1 Omacor® capsule would provide 5-
10 times the daily amount of omega-3 fatty acids consumed by the average person.46 The 
aforementioned studies exploring fish oil in treating psoriasis showed that a significantly 
higher amount was needed to have an effect in this disease. In a review of complementary 
and alternative methods for treating psoriasis Talbott and Duffy looked at other reviews 
focusing on fish oil supplementation in psoriasis and found that in the trials which 
showed a positive effect of fish oil had an average daily dose of 4g of EPA and 2.6g of 
DHA.29 They also found that the average PASI score reduction ranged from 40-75% in 
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these trials and that fish oil as a monotherapy took anywhere from 6 weeks to 6 months to 
show these effects.29  
With such high doses used in these prior trials, subjects would need to consume 8 
Omacor® capsules. Millsop et al.’s review showed several positive trials that used lower 
amounts of EPA and DHA. Two prospective, double-blind placebo controlled trials done 
in England and Germany showed significant improvement with around 2g of EPA and as 
low as 1.2g of DHA.45  
The VITAL trial also explored the safety profile of fish oil supplementation, as it 
has known inhibitory effects on platelet function. They found in their research that the 
FDA stated 3g of fish oil per day was “‘generally recognized as safe” and other studies 
showed that up to 4g per day did not cause any excess bleeding risk.46,48 Omacor® is 
given at 4g per day doses to treat hypertriglyceridemia with no reports of 
“hyperglycemia, abnormal bleeding, elevations in muscle or liver enzymes, and/or 
abnormalities in kidney or nerve function”.47 
Vitamin D 
Vitamin D can manipulate the immune system in several ways including its ability to 
regulate T cell tracking and differentiation as well as keratinocyte proliferation, the two 
major components in the pathogenesis of psoriasis. Vitamin D and its analogues as 
potential psoriasis treatments were discovered 30 years ago in Japan when a patient 
suffering from both osteoporosis and psoriasis was “cured” of his psoriasis during 
treatment for osteoporosis, which prompted research into the use of vitamin D either 
orally or topically in psoriasis.49 Providers have also treated psoriasis patients with 
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phototherapy for years. UVB converts 7-dehydrocholesterol in keratinocytes to 
cholecalciferol (D3), some of which is hydroxylated in the skin to calcitriol (1,25 
(OH)2D3), the active form of vitamin D.11,50 Keratinocytes and T cells both have vitamin 
D receptors (VDRs), which heterodimerize with the retinoid X receptor (RXR). This 
complex binds to specific DNA sequences called vitamin D response elements (VDREs) 
and effects the expression of genes.11  
Prior to the discovery of Th17 and subsequently IL-17 and IL-22 involvement in 
the pathogenesis of this disease it was believed that vitamin D simply interfered with 
proliferation and enhanced differentiation of keratinocytes and had some lymphocyte 
activation regulation.49 The expansion of the understanding of the immunologic basis of 
this disease has lead to further research regarding the mechanism of action of vitamin D 
in psoriatic lesions.  Yamanaka et al. showed that active vitamin D interferes with T cell 
tracking to the skin via alteration of the expression of cutaneous lymphocyte-associated 
antigen (CLA) on T cells, dampening the inflammatory response.51 In a subsequent study 
done by Yamanaka et al. on the vitamin D analog tacalcitrol (1,24 (OH)2 D3) they found 
similar results with less expression of CLA. They also showed that this effect of 
decreased CD4+ skin infiltration occurs not only in a petri dish but also in vivo in mice.52  
Dyring-Anderson et al. studied the expression of CD8+ and CD4+ cells, especially 
those producing IL-17, in psoriatic lesions treated with topical calcipotriol, a vitamin D 
analog. They noted that in 1-3 weeks there was a significant thinning of the psoriatic 
lesions due to decreased keratinocyte proliferation, but the change in T cell profile 
occurred after 4 weeks of treatment. They found after 4 weeks there was an overall 
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decrease in IL-17+ cells, to a point at which CD4+IL-17+ and CD8+IL-17+ were 
undetectable in lesions treated with calcipotriol.11  
 A review by van Etten et al. explored vitamin D interaction with the immune 
system and showed many avenues of immuoregultaion. They found that vitamin D 
targets cytokine transcription of several Th1 cell cytokines and indirectly changes the T 
cell profile to favor a Th2 differentiation and therefore attenuates autoimmunity. 
Although it interacts with T cells, vitamin D’s primary target is the antigen presenting 
cell. Monocytes express much less MHC II when exposed to vitamin D and therefore 
have a reduced ability to stimulate T cells. Vitamin D also inhibits maturation of 
dendritic cells, which are the key initiator of the T cell response. TNF-α expression from 
mature monocytes/macrophages is also downregulated. Unlike many of the products 
available to treat immune system diseases, vitamin D is less immunosuppressive and 
exerts is effect by shifting immune activity and inducing regulatory cells. 53 As of 2008, 
Mora et al. concluded in a review of vitamin A and D immunoregulation that “the net 
result of 1,25(OH)2VD3 action on T cells is to block the induction of T-helper-1 (TH1)-
cell cytokines, particularly IFNγ, while promoting TH2-cell responses”.50 They noted that 
vitamin D also inhibits Th17 via inhibition of other cytokines including IL-23. They 
came to this conclusion based on work done by Daniel et al. that showed a change from a 
Th1/Th17 to Th2 and regulatory T cell profile in mice with colitis who were treated with 
vitamin D.54  
 Many of the aforementioned immunoregulatory properties of vitamin D correlate 
with the immunopathogenic derangements in psoriasis. Multiple studies have shown that 
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psoriatic patients are often vitamin D deficient55–57 and one even showed an inverse 
relationship between vitamin D levels and severity of psoriasis.55 Ricceri et al. performed 
a case-control study exploring vitamin D serum concentrations in patients with psoriasis 
and found that 97% of the cases were at least vitamin D insufficient (<30ng/mL) and 
68% were deficient (<20ng/mL) whereas just over 50% of the controls were insufficient 
and only about 9% were deficient. Furthermore the correlation between serum 
concentration and severity of psoriasis showed a relatively linear, inverse relationship 
with a correlation coefficient of -0.88 (see Figure 2).55  
 
 
 
Figure 2. Inverse relationship of serum vitamin D concentration and the severity of 
psoriasis (from Deficiency of serum concentration of 25-hydroxyvitamin D correlates 
with severity of disease in chronic plaque psoriasis by Ricceri et al.)55	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Aloia et al. performed a study to examine what level of vitamin D3 
(cholecalciferol) intake was necessary to raise serum levels of 25hydroxyvitamin D to a 
sufficient level. They found that an average of 3300IU/day of vitamin D3 was needed to 
reach this goal, but the range was anywhere from 800-6800 given several confounding 
factors (age, sex, gender, weight, ethnicity) and the level of vitamin D deficiency of the 
subject prior to the study.58 
A study by Orgaz-Molina et al. also showed an association of vitamin D 
deficiency with psoriasis as well as an association between markers of metabolic 
syndrome in psoriasis patients and an even lower level of vitamin D. From this they 
hypothesized that vitamin D may be of most benefit in these people who suffer from both 
vitamin D deficiency and metabolic syndrome.59 Prior to that study, Orgaz-Molina et al. 
completed a case-control study, which showed an association of low serum vitamin D 
(25.6% of cases versus 9.3% of controls were deficient) and psoriasis as is commonly 
found in other inflammatory and autoimmune diseases. They reviewed several studies in 
which oral vitamin D supplementation in patients with psoriasis had shown clinical 
improvement and therefore concluded that further studies exploring supplementation 
were warranted.57 
Millsop et al. reviewed multiple vitamin D supplementation studies when 
exploring the effect of diet in psoriasis. In this review they found only one controlled 
study done in 1990, which showed only mild improvement in those supplemented with 
vitamin D and no statistical significance when compared to the control group. However, 
four other uncontrolled studies reviewed by Millsop et al. as well as case study published 
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in 2011 by Werner de Castro et al. showed a range from mild to complete improvement 
in psoriasis with administration of oral vitamin D. 45,60 The case study by Werner de 
Castro et al. showed resolution of medication-induced psoriasiform lesions with high 
dose vitamin D administration.60 Millsop et al.’s review involved the use of several 
different forms of vitamin D (1,25 Dihydroxyvitamin D, 1-Hydroxyvitmain D, 
Cholecalciferol), all of which led to clinical improvement (see appendix B).45 Overall 
these studies showed a moderate improvement in PASI scores with systemic vitamin D, 
but given that these studies are all uncontrolled, further study is warranted. 
 The potential for toxicity is a major hindrance to the use of vitamin D 
systemically in many autoimmune diseases. According to van Etten et al., “high 
supraphysiological doses of 1,25(OH)2D3 have to be given systemically leading to 
detrimental side effects such as hypercalcemia and increased bone resorption” to reach 
immunomodulating levels of vitamin D (10-10 M or higher).53 They state this as the basis 
behind the production of analogs, but they also suggest that this can often be avoided 
with the use of vitamin D in combination therapy rather than as monotherapy. They state 
that vitamin D and its analogs have synergistic effects with other immunomodulators in 
several animal models of autoimmune diseases and post-transplantation.53 
 The use of vitamin D and fish oil in combination is documented in two studies on 
cancer cells. One study done by Chiang et al. explored combination treatment of human 
hepatoblastoma cells. This study also expressed concern about the potential for vitamin D 
toxicity. They explored each treatment individually and in combination. Both treatments 
were found to be effective in a dose dependent manner. They were able to show that by 
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using combination therapy, lower levels of vitamin D could be used with similar anti-
proliferative effects.61 Chatterjee et al. showed a similar effect of combination therapy 
with vitamin D and fish oil in their study on rat mammary carcinogenesis. Administration 
of vitamin D and fish oil in combination had greater suppression of DNA and mRNA 
mutations and retardation of proliferation than either treatment alone.62 Therefore it is 
conceivable that this enhanced anti-proliferative effect could be beneficial in psoriasis as 
well given that keratinocyte proliferation is a major component of this disease.   
Danno and Sugi showed an increased effect of a vitamin A analog and fish oil in 
the treatment of psoriasis in their study of low doses of etretinate in combination with 
EPA. They had faster and greater improvement in chronic plaque psoriasis with 
combination treatment. The efficacy of this low dose etretinate plus EPA treatment was 
equivalent to that of higher dose monotherapy with etreteinate. They were unable to 
comment on whether this was an additive or synergistic relationship.63 Regardless of the 
type of relationship, this study showed a lower level of the potentially toxic etretinate can 
be efficacious as higher dose therapy when used in combination with EPA. 
A study by Marquez- Balbas et al. explored the combination of topical tacalcitol, 
a vitamin D derivative, and oral fish oil in psoriasis and showed enhanced efficacy. The 
reduction in PASI score was almost twice as large in the combination group with a 6.8 
point reduction versus only a 3.5 point reduction in the tacalcitol only control group.35 
The almost 2-fold reduction in PASI scored seen with the combined topical vitamin D 
and oral fish oil therapy demonstrates an additive effect. 
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There is quite a bit of scientific evidence that both fish oil and vitamin D should 
be successful in the treatment of psoriasis. Both of these treatments modulate the immune 
system and have effects on many of the cytokines that are implicated in the pathogenesis 
of this disease. The aforementioned combination studies show that these medications can 
have at least an additive if not a synergistic effect in disorders of excessive proliferation.   
Psoriasis Assessment 
Psoriasis severity is usually classified as mild, mild-moderate, moderate, 
moderate-severe, and severe based on different scales such as the PASI score, body 
surface area (BSA), and/or the Dermatological Life Quality Index (DLQI).14 
Furthermore, the Consensus Guidelines for the Management of Plaque Psoriasis by Hsu 
et al. considers the ability to manage the disease by topicals alone to be the difference 
between mild or moderate versus severe psoriasis.14 In the clinical setting, aspects of 
these scales are often combined to account broadly for a provider’s global assessment of 
disease activity and the affect the disease has on the patient’s quality of life.64  
In addition to formally assessed qualities, patients with psoriasis can also present 
with pruritus, pitting of the nails, onycholysis, pustules, geographic tongue, and arthritis. 
Therefore in clinical practice these formal assessment scales do not provide adequate 
understanding of the burden of the disease. A position paper written by several past and 
present members of the Medical Advisory Board of the NPF and the Board of the NPF 
states that dermatologists “have learned how to assess the severity of disease; this 
assessment includes the needs of the patient, the time needed for treatment, the cost of 
treatment, the benefit of the treatment and the willingness of the patient to accept 
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potential life-altering side effects to achieve a better QOL” and use that to define the 
severity of a patient’s disease. 65 
There are three basic attributes of psoriatic lesions that providers assess: redness, 
thickness, and degree of scale. As mentioned above these can be relatively subjective 
characteristics.  In a review of assessment methods by Langley and Ellis they stated 
“PASI was developed in 1978 by Fredricksson and Pettersson8 for use in a single clinical 
trial. Subsequently, the PASI became popular as a research tool but is not used in clinical 
practice.”66 The PASI has been considered the gold standard for clinical trials67 as it 
addresses the aforementioned attributes, but it has been shown to be less sensitive to 
changes in smaller lesions.64 Many also feel that the PASI assessment is time consuming, 
difficult to interpret, and can be insensitive to those with mild to moderate disease.67 
Schmitt and Wozen make the argument that, despite its shortcomings, the PASI is 
still the best studied, most objective assessment method for psoriasis.15 In clinical trials, 
evidence based medicine, and approval by the FDA, a method of formal, objective 
assessment is needed. Walsh et al. explain that the PASI is “widely considered the gold 
standard measure of disease severity and is frequently used as a primary efficacy end 
point in clinical trials of moderate to severe psoriasis” but it does have shortcomings in 
mild disease and is cumbersome to use.67 They also explained that in recent years the 
FDA has also required the use of the static Physician Global Assessment for most of the 
last phase III clinical trials. This method however does not take into account the BSA,67 
which is a major component of the disease. Exploration of new and improved systems of 
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psoriasis evaluation is ongoing. New methods are being tested against known standard 
scales, but none are commonly used at this time. 
PASI 
The PASI score assessment scale is still the most widely used method for clinical trials. It 
splits the body up into head, arms, trunk and legs and requires the clinician to provide a 
percentage surface area of each section. The degree of erythema, scale and thickness of 
each of these sections is also given a score from 0-4 (see appendix C). The percent 
surface area and these scores are computed into a final PASI score ranging from 0-72. 
There are several calculators available which will compute the PASI score given these 
data points. 	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METHODS 
Study design 
This study will be a randomized, placebo-controlled clinical trial examining the use of 
vitamin D and fish oil in combination to treat psoriasis.  
Study population and sampling 
The study population will be selected from several clinics in or around the city of Boston 
who meet the inclusion and exclusion criteria. Given that there is an interest in the effect 
of the proposed intervention on patients with varying degrees of severity, patients will not 
be excluded if they are currently taking medication as this would most likely result in few 
patients with severe or even moderate disease. Inclusion and exclusion criteria are in 
table 3.  
Table 3. Inclusion and Exclusion criteria 
 
Inclusion Exclusion 
18 years or older 
Recently started, new psoriasis medication 
(oral/topical within 3 months) 
Diagnosed with chronic plaque psoriasis Only arthritic or pustular presentation 
Stable disease after being on current 
regimen for at least 3 months 
Taking vitamin D or fish oil 
supplementation prior to study 
Any level PASI or body surface area 
Expecting prolonged periods of sun 
exposure during study 
(>10 days of >3hrs/day) 
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 A sample size of 63 participants in each group for a total of 126 total will yield 
80% power to detect a 50% reduction in PASI score with an alpha of 0.05.68 
Treatment  
The study will have two arms, one that receives vitamin D and fish oil supplementation 
and one that receives placebo pills. The study population will be randomized into these 
two groups. It will be double-blinded and the study coordinator will do the randomization 
prior to the initial evaluation by the study clinician.  
The proposed treatment will be four Omacor® fish oil capsules and two 2000 IU 
vitamin D3 (cholecalciferol) tablets per day. This will provide 1.8g EPA, 1.5g DHA, and 
4000IU of cholecalciferol. These pills will be given to the patient in 12 week supplies and 
the patient will be asked to bring the bottles to their 12 week appointments as a simple 
way to monitor compliance.    
Study variables and measures 
The method of assessment used in this trial will be the PASI score as determined by the 
study clinician. The data will be put into the PASI calculator on pasitraining.com. This 
site also provides training on how best to estimate the percentage of each body section 
via eyeball or palmar method and how to score the degree of each of the three 
characteristics judged by this scale.69  
Institutional Review Board 
A proposal will be submitted for full IRB approval. This study would fall into the full 
review category, as it is a randomized, double-blinded clinical trial using a placebo. 
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Recruitment 
Patients will be obtained via provider referral from several clinics around Boston. The 
need for patients for this study will be expressed in a letter given to local clinics and it 
will ask for providers to seek out patients who meet the aforementioned inclusion and 
exclusion criteria and are interested in participating in a study. These may be patients that 
wish to find alternative ways to treat their psoriasis as an alternative to traditional 
methods or it may be those who wish to supplement their current regimen. 
Data collection 
All subjects will have an initial visit with a study-associated clinician at which time, 
following appropriate consent procedures, a baseline PASI score and photographs will be 
taken. The same clinician will perform all the subsequent exams in an effort to minimize 
the subjective nature of the PASI scoring system.  The baseline vitamin D level will also 
be measured at this visit. This initial visit will be performed in a rolling fashion so as to 
provide ample time for a single evaluator to see all enrolled subjects. At 12 week 
intervals the subjects will return for evaluation and photographs by the same clinician. 
Vitamin D levels will be drawn at each visit. The study will continue for 1 year.  
Data analysis 
The PASI scores will be measured by their change from the baseline score. This will 
show the absolute benefit to each individual subject. It will also provide a more 
standardized measure of the effect of the treatment as subjects may have a wide variety of 
baseline PASI scores. A reduction in absolute score may be vastly different between 
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mild, moderate and severe disease, which would make statistical analysis between the 
two treatment arms difficult.  
 Mean, median, range and standard deviation will be calculated based on PASI 
scores. Pre-and-post intervention PASI scores will be compared via Paired t-Test and the 
intervention and control group means compared with a two-sided Student’s t-Test. 
Correlation between vitamin D levels and percent PASI reduction will be analyzed using 
Pearson’s correlation coefficient. Subgroup analysis will be done on patients classified as 
mild, moderate, and severe to see if there is a statistically significant difference in effect 
depending on the baseline severity of disease.  The analysis will be done using an 
intention-to-treat regardless of patient adherence. 
Timeline and resources 
Personnel 
• Study coordinator 
• Clinician for PASI assessment, photographs 
• Technician for blood draw 
• Primary Investigator 
• Statistician 
Special Resources 
• Laboratory Assay 
• Camera 
• Fish oil and vitamin D capsules, similar-appearing placebo pills 	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Table 4. Timeline 	  
April-August 2016 • IRB proposal submitted/approved 
September 2016 – April 
2017 
• Letter sent to providers in Boston 
• Identification of subjects 
September 2016-April 
2018 
• Initial assessment by study appointed clinician 
• Initial blood draw 
• Administration of intervention with four 12 week 
follow up assessments/ blood draws 
Fall 2017-Spring 2018 • Final visit at the end of year of treatment 
Spring 2018 
• Data analysis 
• Preparation and submission of manuscript 
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CONCLUSION 
Discussion 
To date this investigator was unable to find studies exploring a combination of systemic 
vitamin D and fish oil. Both of these supplements have known anti-proliferative and anti-
inflammatory effects. Fish oil modulates the cytokines produced by skin cells as well as 
the immune profile by regulating the differentiation of CD4+ T cells. Vitamin D also 
influences this systemic T cell profile, mainly acting on the antigen presenting cells. By 
acting on two different levels of T cell differentiation, both of these supplements promote 
a less inflammatory, Th2, immune profile. This study will look at the possible additive 
effects of these supplements in this highly inflammatory disease. 
The proposed study is limited in regards to its ability to accurately assess the 
effect of the proposed intervention without confounding variables. The exclusion criteria 
are aimed at limiting these so that the observed effects are most likely due to the 
intervention. The subjects will have different pre-study treatment regimens.  This study 
will require these be unchanged over the 3 months prior to participation and that they be 
held constant for the duration. It is unethical to stop a patient’s treatment regimen if the 
regimen has a positive effect and the efficacy of the proposed intervention is 
controversial.  Psoriasis is a disease with a natural ebb and flow in disease severity, at 
times correlated with weather. This could also skew the study findings. A rolling 
admission to the study over a 6 month timeframe aims to partially minimize the effects of 
this potential confounder.	   Another limitation would be that all subjects in this study will 
be living in Massachusetts and therefore might have a different baseline vitamin D level 
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than patients in other parts of the country. Our results may not be generalizable to other 
locations. A final potential limitation of this study could be that the PASI scoring system 
is less sensitive to change in mild disease, often defined as less than 10% body surface 
involvement.   
This study will provide information about the effects of the proposed treatment on 
varying degrees of psoriasis severity. The generalizability of the findings of this study 
will be based on the ability to attract a diverse group of subjects, which is likely in the 
Boston area. 
The greatest strength of this study is the fact that it proposes a novel intervention 
in the management of psoriasis. Investigators have researched each of these supplements 
alone for psoriasis or in combination for other diseases, but never in combination for the 
treatment of psoriasis. Another advantage is that it will be a placebo-controlled trial, 
whereas many of the studies on fish oil or vitamin D alone were not. 	  
Summary 
Many genes on several genetic loci are common to psoriasis patients, but environmental 
factors also play a large role in regulating disease severity and prevalence. Psoriasis is a 
disease of T-cell mediated inflammation regulated by pro-inflammatory cytokines 
produced by immune cells as well as the keratinocytes themselves. These cytokines in 
turn create a pro-inflammatory Th1 and Th17 immune profile, which is the target of 
many of the medications used to treat this disease.  
 The available treatments for psoriasis have many undesirable potential side 
effects, are often cumbersome to use and can be prohibitively expensive. This experiment 
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aims to eliminate all three of these pitfalls by exploring natural supplements that are 
taken orally only once per day and can be purchased over the counter at a drug store or 
grocery store. 
 Both omega-3 fish oil and vitamin D have been tested in the past as possible 
treatments for psoriasis. The literature shows that higher than average doses of both of 
these supplements can result in a significant reduction in psoriasis severity. Further 
studies that explored combining these supplements to prevent and to treat cancer have 
also shown promising results. Combining fish oil with retinoids used to treat psoriasis 
was shown to reduce the amount of the potentially toxic retinoid needed to provide 
significant results. These findings suggest that combining fish oil and vitamin D, 
treatments that have been shown to work on their own, could have an additive or even 
synergistic effect when treating psoriasis.  
 This study will provide data supporting or refuting the efficacy of this 
inexpensive, simply administered, and safe alternative to the psoriasis medications that 
are on the market today. It could also provide information about using this treatment 
strategy to complement existing regimens rather than stepping up to a stronger 
immunomodulating agent with more potential adverse events. 
Clinical and/or public health significance 
As mentioned above, if the data from this project show significant improvement in 
psoriasis with these natural supplements, it could add a complementary treatment option 
to a provider’s arsenal. Many patients shy away from medications with a long list of 
potential side effects or those that make them change their lifestyle. This proposed 
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treatment could eliminate many of those tribulations. This would benefit patients, but also 
providers who often struggle with patient compliance, particularly in those with mild 
disease. Furthermore, the ever-expanding literature connecting psoriasis with metabolic 
disorder and cardiovascular disease makes this proposed treatment, which includes a 
supplement known to have benefit in CVD, even more enticing.    
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APPENDIX A 
 “Studies examining the efficacy of fish oil supplementation in psoriasis” Adapted 
from Table 1 in Diet and Psoriasis, Part III: Role of Nutritional Supplements45 
Study No. of patients 
EPA 
dose g/d 
DHA 
dose g/d Results 
Mayser et al, 
1998 
(controlled) 
75 4.2 4.2 
PASI score decreased by 11.2 ± 
9.8 in the omega-3 group and by 
7.5 ± 8.8 in the omega-6 group  
(P = .048) 
Bittiner et al, 
1988 
(controlled) 
28 at 8 
wk; 24 at 
12 wk 
1.8 1.2 
Improvement in: erythema P  
< .05 at 8 and 12 wk; itching at 8 
wk P < .05 in treatment group vs 
control 
Grimminger et 
al, 1993 
(controlled) 
20 2.1 2.1 
Greater improvement in 
erythema, infiltration, 
desquamation in omega-3 group 
compared with omega-6 group (P 
< .05 for all categories) 
Lassus et al, 
1990 
(uncontrolled) 
76 1.1 0.8 
Decrease in mean PASI score 
after 4 and 8 wks (P < .001); 7 
patients with complete response; 
13 with >75% improvement; 14 
with poor response 
Kragballe and 
Fogh, 1989 
(uncontrolled) 
26 5.4 3.6 
Moderate-excellent improvement 
in 15/26 (58%) patients; mild 
improvement in 5/26 (19%); no 
change in 6/26 (23%) 
Kragballe, 1989 
(uncontrolled) 17 0.54 0.36 
Moderate-excellent improvement 
in 10 patients; mild improvement 
in 4; no change in 3 
Ziboh et al, 1986 
(uncontrolled) 13 
10.8-
13.5 7.2-9.0 
Improvement in: scaling (P < 
.001); erythema (P < .02); 
thickness (P < .004); 8/13 (62%) 
subjects demonstrated "clinically 
significant" improvement 
Maurice et al, 
1987 
(uncontrolled) 
10 12 8 
8/10 (80%) Showed modest 
improvement in erythema in 
scale 
Kojima et al, 
1989 9 3.6 - 
At 6 mo, 2/7 (29%) showed 
marked improvement, 4/7 (57%) 
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(uncontrolled) moderate improvement, and 1/7 
(14%) no improvement 
Danno and 
Sugie, 1998 
(controlled) 
40 1.8 - 
More patients showed "excellent 
clinical improvement" by >75% 
reduction in clinical scores in 
treatment group 
Balbas et al, 
2011 
(controlled) 
30 5.6 0.8 
Improvement statistically greater 
in treatment group compared 
with control for PASI score (P < 
.0001), DLQI (P = .0056), 
pruritus (P < .0001) 
Gupta et al, 1989 
(controlled) 18 3.6 2.4 
Fish oil group improved more 
than olive oil group in erythema 
(P = .02), thickness (P = .006), 
scale (P = .008), and total body 
surface area (P = .0001) 
Soyland et al, 
1993 
(controlled) 
145 3.1 1.9 
No significant difference in 
change in PASI score, scaling, 
erythema, infiltration of selected 
area between treatment vs control 
group 
Bjorneboe et al, 
1988 
(controlled) 
27 1.8 1.2 
No significant change in clinical 
scores of erythema, infiltration, 
desquamation, and surface area 
in either group 
Kettler et al, 
1988 
(uncontrolled) 
23 3.2 2.2 
Significant improvement only in 
the 1 patient with pustular 
psoriasis; minimal improvement 
in 8 patients; no change in 10; 
mild worsening in 5 
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APPENDIX B 
“Studies examining vitamin D supplementation in psoriasis” adapted from Table II 
in Diet and Psoriasis, part III: Role of Nutritional Supplements by Millsop et al.45 
Study No. of patients 
Vitamin D3 form 
dose, µg/d Results 
Perez et al., 
1996 
(uncontrolled) 
85 
1,25-
DihydroxyStarted at 
0.5 and increased by 
0.5 every 2 wk as 
long as 24-h urinary 
calcium 
concentrations 
remained normal 
26.5% Had complete improvement; 
36.2% had moderate improvement; 
25.3% had slight improvement; 
mean PASI score 18.4 ± 1.0 at 
baseline, 9.7 ± 0.8 at 6 mo, 7.8 ± 1.3 
at 24 mo 
Siddiqui et al., 
1990 
(controlled) 
41 1-Hydroxy 1.0 
9/20 (45%) on Vitamin D showed 
slight improvement vs 8/21 (38%) 
on placebo showed slight 
improvement, no statistically 
significant difference 
Morimoto et 
al., 1986 
(uncontrolled) 
17 1-Hydroxy 1.0 
76% of Patients displayed moderate 
or greater improvement after 2.7 ± 
0.6 mo 
Smith et al., 
1988 
(uncontrolled) 
14 1,25-Dihydroxy 0.5-2.0 
7/14 (50%) Improved >75%; 3/14 
(21%) improved 25%-50%; 4/14 
(29%) improved 0%-25% 
Finamor et al., 
2013 
(uncontrolled) 
9 Cholecalciferol  875.0 
There was a statistically significant 
improvement in PASI scores from 
baseline to 6 mo (P < .01); PASI 
scores inversely correlated with 
serum 25-hydroxyvitamin D3 levels 
(P < .001) 
el-Azhary et 
al., 1993 
(uncontrolled) 
8 1,25-Dihydroxy 0.5-2.0 
1/8 (12.5%) Improved markedly; 1/8 
(12.5%) improved moderately; 6/8 
(75%) with no or mild improvement 
Takamoto et 
al., 1986 
(uncontrolled) 
7 1-Hydroxy 1.0 
2/7 (29%) Showed complete 
remission; 2/7 (29%) showed 
marked improvement; 3/7 (43%) 
showed no improvement 
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APPENDIX C 
Psoriasis Area and Severity Index 
 
Head	   	   	   	   	   	   	  
Area ¢0%   ¢<10%   ¢10-29%   ¢30-49%   ¢50-69%   ¢70-89%   ¢90-100% 
Erythema  ¢0 ¢1 ¢2 ¢3 ¢4    
Induration  ¢0 ¢1 ¢2 ¢3 ¢4    
Desquamation  ¢0 ¢1 ¢2 ¢3 ¢4    
 
Trunk 
Area ¢0%   ¢<10%   ¢10-29%   ¢30-49%   ¢50-69%   ¢70-89%   ¢90-100% 
Erythema  ¢0 ¢1 ¢2 ¢3 ¢4 
Induration  ¢0 ¢1 ¢2 ¢3 ¢4 
Desquamation  ¢0 ¢1 ¢2 ¢3 ¢4 
 
Upper Extremities 
Area ¢0%   ¢<10%   ¢10-29%   ¢30-49%   ¢50-69%   ¢70-89%   ¢90-100% 
Erythema  ¢0 ¢1 ¢2 ¢3 ¢4 
Induration  ¢0 ¢1 ¢2 ¢3 ¢4 
Desquamation  ¢0 ¢1 ¢2 ¢3 ¢4 
 
Lower extremities 
Area ¢0%   ¢<10%   ¢10-29%   ¢30-49%   ¢50-69%   ¢70-89%   ¢90-100% 
Erythema  ¢0 ¢1 ¢2 ¢3 ¢4 
Induration  ¢0 ¢1 ¢2 ¢3 ¢4 
Desquamation  ¢0 ¢1 ¢2 ¢3 ¢4  
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LIST OF JOURNAL ABBREVIATIONS 
Acta Derm Venereol Acta Dermato Venereologica 
Adv Nutr Advances in Nutrition 
Am J Cardiol The American Journal of Cardiology 
Am J Clin Dermatol The American Journal of Clinical Dermatology 
Am J Clin Nutr The American Journal of Clinical Nutrition 
Ann Rheum Dis Annals of the Rheumatic Diseases 
Anticancer Res Anticancer Research 
Arch Dermatol Archives of Dermatology 
Br J Dermatol British Journal of Dermatology 
Br J Nutr British Journal of Nutrition 
Chem Biol Interact Chemico-Biological Interactions 
Clin Cosmet Investig Dermatol Clinical, Cosmetic and Investigative Dermatology 
Clin Dermatol Clinics in Dermatology 
Contemp Clin Trials Contemporary Clinical Trials 
Cytokine Growth Factor Rev Cytokine & Growth Factor Reviews 
Dermatol Clin Dermatologic Clinics 
Dermatol Online J Dermatology Online Journal 
Expert Opin Drug Saf Expert Opinion on Drug Safety 
Expert Opin Investig Drugs Expert Opinion on Investigational Drugs 
Expert Rev Clin Immunol Expert Review of Clinical Immunology 
Int Heart J International Heart Journal 
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J Allergy Clin Immunol Journal of Allergy and Clinical Immunology 
J Am Acad Dermatol Journal of the American Academy of Dermatology 
JAMA Dermatol The Journal of the American Medical Association 
Dermatology 
J Autoimmun Journal of Autoimmunity 
J Bone Miner Res Journal of Bone and Mineral Research 
J Clin Endocrinol Metab The Journal of Clinical Endocrinology & Metabolism 
J Dermatol The Journal of Dermatology 
J Eur Acad Dermatol Venereol Journal of the European Academy of Dermatology and 
Venereology 
J Invest Dermatol Journal of Investigative Dermatology 
J Nutr The Journal of Nutrition 
J Pharmacol Exp Ther Journal of Pharmacology and Experimental 
Therapeutics 
Mol Immunol Molecular Immunology 
Nat Rev Immunol Nature Reviews Immunology 
N Engl J Med New England Journal of Medicine 
PLEFA Prostaglandins, Leukotrienes and Essential Fatty Acids 
Postgrad Med Postgraduate Medicine 
Psoriasis Targets Ther Psoriasis Targets and Therapy 
Rheumatol Int Rheumatology International 
Scand J Immunol Scandinavian Journal of Immunology 
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Steroid Biochem Mol Biol The Journal of Steroid Biochemistry and Molecular 
Biology 
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• 20 min presentation 
 
Benign or Malignant: SK, Atypical Nevus,         Boston University PA Program 
Melanoma             2015 
• 20 min presentation      
 
Delusional Infestation       West Roxbury VA Medical Center 
• 30 min presentation           2015
           
COMMUNITY SERVICE 
   
Life Guard Skin Cancer Screening        Dermatology of Cape Cod 
• Registering and rooming patients, taking histories        2005-2013 
 
LEADERSHIP 
 
Massachusetts Academy of Physician Assistants            PA Day on Beacon Hill 
• Lobbied a bill to recognize Physician Assistants        2015 
as healthcare providers under MassHealth insurance  
to Massachusetts State Legislators 
 
 
